<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:image="http://www.sitemaps.org/schemas/sitemap-image/1.1"
        xmlns:video="http://www.sitemaps.org/schemas/sitemap-video/1.1">

	
		
		

		

		
			
				<url>
					<loc>https://8934a.iqanda-cme.com/</loc>
					<lastmod>2019-06-06T23:37:19+0000</lastmod>
					<changefreq>weekly</changefreq>
					<priority>1</priority>
				</url>
				
			
		

		
		

			
			
			
			
		

		
	


			<url>
				<loc>https://8934a.iqanda-cme.com/about-iqanda-extracorporeal-photopheresis</loc>
				<lastmod>2021-02-18T21:10:26+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/submit-a-question</loc>
				<lastmod>2019-04-08T22:52:25+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/extracorporeal-photopheresis</loc>
				<lastmod>2020-12-14T22:38:15+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-provide-an-overview-of-the-clinical-and-pathologic-findings-of-ctcl</loc>
				<lastmod>2019-04-10T00:31:21+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-is-the-role-of-measuring-t-cell-counts-when-you-employ-ecp-for-ctcl</loc>
				<lastmod>2019-04-10T00:59:53+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-are-the-contraindications-to-ecp</loc>
				<lastmod>2019-04-10T01:13:56+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/from-a-practical-implementation-perspective-what-kind-of-ports-are-available-for-ecp-and-what-is-the-recommended-schedule-for-deploying-ecp-in-both-acute-and-chronic-gvhd-on-what-basis-was-this-schedule-determined</loc>
				<lastmod>2019-04-09T23:06:07+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/given-the-multiple-clinical-phenotypes-and-subtypes-that-are-observed-with-systemic-sclerosis-what-therapeutic-approaches-are-aligned-with-what-forms-of-the-disease-and-what-is-the-evidence-based-role-for-ecp</loc>
				<lastmod>2019-04-09T23:48:09+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-have-your-own-meta-analyses-as-well-as-others-conducted-in-the-uk-shown-as-far-as-response-rates-to-ecp-in-patients-with-advanced-ctcl</loc>
				<lastmod>2019-04-10T00:46:23+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/how-do-you-identify-patients-with-ctcl-who-are-likely-to-be-highly-responsive-to-ecp</loc>
				<lastmod>2019-04-10T01:07:42+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/how-enduring-is-the-response-to-ecp-in-appropriately-selected-patients-with-ctcl-what-percentage-of-ctcl-patients-who-have-failed-initial-therapy-can-be-expected-to-respond-and-what-are-the-characteristics-of-the-dose-response-curve</loc>
				<lastmod>2019-04-09T20:21:57+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/since-you-and-others-at-yale-have-treated-a-number-of-patients-with-scleroderma-and-other-conditions-with-ecp-can-you-share-your-real-world-clinical-experience-with-this-treatment-modality-and-how-measure-clinical-response-to-this-therap</loc>
				<lastmod>2019-04-10T00:03:54+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-explains-the-bi-directional-immunomodulatory-and-therapeutic-effects-of-ecp-and-what-are-the-practical-implications-of-its-deployment-against-a-broad-spectrum-of-disease-states</loc>
				<lastmod>2019-04-09T20:28:28+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-are-the-most-important-randomized-studies-that-support-ecp-and-what-do-we-still-need-to-know-about-ecp-as-a-foundational-second-line-treatment-strategy-for-gvhd</loc>
				<lastmod>2019-04-09T23:21:54+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-length-of-time-is-typically-required-to-determine-whether-ecp-has-been-effective-for-cgvhd-and-when-might-you-consider-discontinuation-of-ecp-based-on-a-clinical-response-to-ecp-what-is-the-accepted-tapering-schedule-in-responders</loc>
				<lastmod>2019-04-09T23:13:28+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/from-a-top-line-perspective-what-is-the-mechanism-of-ecp-in-the-setting-of-ctcl</loc>
				<lastmod>2019-04-10T01:28:30+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/are-there-specific-variants-or-clinical-signatures-of-chronic-cgvhd-that-respond-better-to-ecp-therapy-than-others-what-other-second-line-therapies-including-ibrutinib-have-been-evaluated-and/or-fda-approved</loc>
				<lastmod>2019-04-09T22:46:23+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/based-on-clinical-trial-data-the-benefit-to-risk-equation-contraindications-and-experience-with-ecp-at-your-institution-which-patients-with-scleroderma-are-you-treating-with-ecp-and-what-strategies-are-you-deploying-to-optimize-outcomes</loc>
				<lastmod>2019-04-09T23:57:31+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/although-corticosteroids-are-the-standard-first-therapy-for-chronic-cgvhd-graft-versus-host-disease-and-multiple-second-line-treatments-have-been-evaluated-for-patients-who-are-steroid-refractory-or-steroid-intolerant-what-role-does-ecp-</loc>
				<lastmod>2019-04-10T04:49:08+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-did-the-initial-trials-show-efficacy-and-safety-wise-in-patients-with-ctcl-who-were-treated-with-ecp</loc>
				<lastmod>2019-04-10T00:42:43+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-provide-a-brief-review-of-scleroderma-systemic-sclerosis-as-a-multisystem-connective-tissue-disease-characterized-by-humoral-and-cellular-immune-abnormalities-and-fibroblast-activation</loc>
				<lastmod>2019-04-09T23:45:07+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-is-the-approach-to-using-ecp-in-a-patient-with-erythroderma-and-when-in-the-time-course-of-the-natural-history-of-ctcl-do-these-patients-usually-present-to-you-for-consideration-of-ecp</loc>
				<lastmod>2019-04-10T01:23:58+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-are-the-immunological-criteria-and/or-clinical-factors-that-must-be-met-in-order-to-identify-patients-with-advanced-ctcl-who-are-likely-to-respond-to-ecp-provide-a-systematic-approach-including-assessment-of-cd8-t-cell-count-for-scr</loc>
				<lastmod>2019-04-09T20:29:18+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-take-us-through-a-typical-patient-with-ctcl-that-you-would-evaluate-treat-and-finally-determine-the-evidence-and-suitability-of-this-patient-for-treatment-with-ecp</loc>
				<lastmod>2019-04-10T01:20:16+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/from-a-clinical-perspective-how-do-you-sequence-therapies-for-patients-with-ctcl-what-is-the-initial-modality-and-why-and-when-does-ecp-represent-an-evidence-based-approach-to-treating-ctcl-how-many-ecp-treatments-and-at-what-frequency</loc>
				<lastmod>2019-04-09T20:30:12+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-characterize-the-signs-symptoms-and-complications-of-allogeneic-cell-transplant-in-particular-acute-and-chronic-gvhd-can-you-distinguish-between-these-two-forms-of-gvhd-what-were-the-classifications-provided-by-the-nih-consensus</loc>
				<lastmod>2019-04-09T22:53:59+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/as-a-pioneer-in-the-field-of-extracorporeal-photopheresis-ecp-can-you-provide-some-background-and-history-on-how-this-therapeutic-strategy-was-developed-and-for-what-challenging-conditions-in-particular-in-ctcl</loc>
				<lastmod>2019-04-10T02:22:43+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/has-access-to-the-technology-required-for-implementing-ecp-improved-over-the-past-years-and-if-so-why</loc>
				<lastmod>2019-04-10T01:30:52+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-treatment-modalities-are-currently-used-for-ctcl-prior-to-employing-ecp</loc>
				<lastmod>2019-04-10T00:34:10+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-findings-of-progressive-skin-involvement-with-scleroderma-are-clinical-triggers-to-warrant-consideration-of-ecp-in-the-heterogeneous-population-of-patients-what-is-the-clinical-trial-data-supporting-the-use-of-ecp-in-scleroderma</loc>
				<lastmod>2019-04-09T23:54:13+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/once-you-and-colleagues-in-the-field-had-determined-that-dendritic-presenting-cells-dpcs-were-critical-mediators-of-the-therapeutic-effects-of-ecp-how-did-you-determine-the-actual-mechanism-by-which-ecp-activated-dpcs</loc>
				<lastmod>2019-04-09T20:28:07+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-is-the-safety-and-adverse-effect-profile-of-ecp-in-your-experience-and-how-often-do-they-occur</loc>
				<lastmod>2019-04-10T01:10:48+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/once-you-have-made-the-decision-to-deploy-ecp-as-your-second-line-therapy-for-steroid-refractory-agvhd-or-cgvhd-what-practical-considerations-should-clinicians-be-knowledgeable-of-when-considering-ecp-treatment</loc>
				<lastmod>2019-04-09T23:09:35+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/at-your-institution-how-long-is-each-ecp-treatment-session-and-how-long-do-patients-with-ctcl-typically-require-treatment-within-what-period-do-you-expect-to-see-a-treatment-response</loc>
				<lastmod>2019-04-10T01:03:42+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-is-the-degree-of-steroid-sparing-effect-that-can-be-anticipated-when-using-ecp-to-treat-gvhd-and-what-complications-should-be-considered-to-be-part-of-an-ecp-dominant-treatment-strategy-for-gvhd</loc>
				<lastmod>2019-04-10T04:51:53+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/do-you-typically-employ-ecp-in-patients-with-ctcl-as-monotherapy-or-in-conjunction-with-other-systemic-pharmacologic-or-immune-based-treatments</loc>
				<lastmod>2019-04-10T00:49:57+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-discuss-the-findings-implications-consensus-agreements-and-recommendations-issued-by-the-american-council-of-extracorporeal-photopheresis-ace-which-was-commissioned-by-asfa</loc>
				<lastmod>2019-04-09T20:28:57+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-is-the-role-of-ecp-in-steroid-refractory-patients-with-gvhd-and-what-is-the-evidence-confirming-acceptable-response-rates-and-safety-of-ecp-in-these-patient-populations</loc>
				<lastmod>2019-04-09T23:02:19+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-discuss-what-is-unique-about-ecp-and-why-this-therapy-provides-an-acceptable-balance-of-efficacy-and-safety-for-malignant-conditions-as-well-as-related-conditions</loc>
				<lastmod>2019-04-10T02:23:46+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-is-the-schedule-i-e-frequency-of-ecp-treatments-that-patients-with-scleroderma-require-and-what-are-the-possible-side-effects-that-require-monitoring</loc>
				<lastmod>2019-04-10T00:00:05+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-summarize-the-mechanistic-underpinnings-of-ecp-and-its-role-in-anti-cancer-therapy-and-future-applications</loc>
				<lastmod>2019-04-09T20:25:45+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/how-do-you-taper-corticosteroid-therapy-in-acute-and-chronic-gvhd</loc>
				<lastmod>2019-04-09T23:27:49+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/how-do-you-manage-patient-expectations-whom-you-are-committing-to-ecp</loc>
				<lastmod>2019-04-10T01:26:17+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/in-what-specific-patient-populations/disease-states-is-allogeneic-hematopoietic-cell-transplantation-hct-an-important-therapeutic-option</loc>
				<lastmod>2019-04-09T22:51:06+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-role-does-ecp-play-in-patients-with-ctcl-with-progressive-disease-and/or-those-who-have-not-responded-to-initial-systemic-immune-modifying-or-skin-directed-therapy</loc>
				<lastmod>2019-04-10T00:37:51+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/what-is-the-difference-between-acute-and-chronic-gvhd-how-is-the-diagnosis-of-gvhd-made-how-is-each-condition-treated-what-is-the-role-of-steroids-as-current-soc-and-what-percentage-of-patients-are-steroid-refractory-and-potentially-requ</loc>
				<lastmod>2019-04-09T22:59:20+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-be-specific-about-how-you-interpret-the-results-of-the-cd4/cd8-t-cell-ratios-in-order-to-determine-suitability-for-ecp-therapy-and-what-is-the-role-of-anti-t-cell-antibodies-for-patient-screening</loc>
				<lastmod>2019-04-09T20:29:37+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/videos/can-you-explain-the-importance-of-the-fact-that-ecp-provides-dual-or-bifurcated-effects-on-immune-modulation-i-e-it-can-potentiate-immune-response-against-malignancies-such-as-ctcl-and-tolerize-immune-response-in-such-conditions-as-gvhd</loc>
				<lastmod>2019-04-10T02:24:20+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/courses/focus-on-the-evidence-and-clinical-applications-for-ctcl-gvhd-solid-organ-transplant-rejection-and-scleroderma</loc>
				<lastmod>2023-04-14T03:32:47+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/cutaneous-t-cell-lymphoma-diagnosis-risk-stratification-and-management</loc>
				<lastmod>2019-04-09T22:28:09+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/program-agenda-and-complete-faq-list</loc>
				<lastmod>2019-04-09T22:27:12+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/ecp-consensus-statement-update-from-the-uk-photopheresis-society</loc>
				<lastmod>2019-04-09T22:29:41+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/ecp-in-gvhd-evidence-and-opinion</loc>
				<lastmod>2019-04-09T22:28:38+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/an-exploratory-cost-effectiveness-analysis-of-systemic-treatments-for-cutaneous-t-cell-lymphoma</loc>
				<lastmod>2019-04-09T22:27:48+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/guidelines-for-the-use-of-ecp-in-gvhd</loc>
				<lastmod>2019-04-09T22:28:52+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/ecp-an-overview</loc>
				<lastmod>2019-04-09T22:29:28+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/mechanistic-insights-into-extracorporeal-photochemotherapy</loc>
				<lastmod>2019-04-09T22:27:29+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/guidelines-on-the-use-of-extracorporeal-photopheresis</loc>
				<lastmod>2019-04-09T22:29:13+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
			<url>
				<loc>https://8934a.iqanda-cme.com/flexpaper/extracorporeal-photopheresis-as-a-treatment-modality-for-acute-and-chronic-graft-versus-host-disease</loc>
				<lastmod>2019-04-09T22:28:23+0000</lastmod>
				<changefreq>weekly</changefreq>
				<priority>0.8</priority>
			</url>
			
</urlset>